Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Vaxin Inc.
ClinicalTrials.gov Identifier:
NCT00755703
First received: September 17, 2008
Last updated: September 11, 2012
Last verified: September 2012

September 17, 2008
September 11, 2012
October 2008
September 2009   (final data collection date for primary outcome measure)
To assess the safety of a nasally administered adenovirus-vectored pandemic influenza vaccine in healthy human adults. [ Time Frame: 56 day observations with 2 year follow-up ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00755703 on ClinicalTrials.gov Archive Site
Determination of immunogenicity and correlates of protection based on HI titers in vaccinates [ Time Frame: 28 days and 56 days post vaccination ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Safety and Immunogenicity Study of Adenovirus-vectored, Intranasal Pandemic Influenza Vaccine.
A Phase I, Dose-Ranging Safety and Immunogenicity Study of an Adenovirus-vectored Intranasal, Pandemic (Hemagglutinin H5) Influenza Vaccine, ADhVN1203/04.H5, in Healthy Adults

The purpose of this study is to test the recombinant vaccine for safety and immunogenicity in healthy adults volunteers. Single dose, intranasally administered vaccine using an adenovirus-recombinant vector has provided a safe route for inducing protection in animals against pandemic influenza in preclinical studies.

The vaccine is non-replicating, tissue culture based and designed for intranasal delivery.

Objectives:

The primary objective is to evaluate the safety of the AdhVN1203/04.H5 vaccine when administered intranasally in two doses with an interval of 28 days in healthy adults 19-49 years of age.

The secondary objective is to evaluated the immunogenicity of the AdhVN1203/04.H5 vaccine at three different doses (10e8, 10e9 and 10e10 viral particles) when administered intranasally in two doses with an interval of 28 days in healthy adults 19-49 years of age.

Interventional
Phase 1
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Influenza A Subtype H5N1 Infection
Biological: Pandemic Influenza Vaccine
Undetermined
  • Experimental: Group 1
    There will be 12 subjects in Group 1 that will receive 10e8 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
    Intervention: Biological: Pandemic Influenza Vaccine
  • Experimental: Group 2
    There will be 12 subjects in Group 2 that will receive 10e9 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
    Intervention: Biological: Pandemic Influenza Vaccine
  • Experimental: Group 3
    There will be 12 subjects in Group 3 that will receive 10e10 viral particles of the Pandemic Influenza Vaccine administered via intranasal spray on day 0 and day 28 (+/- 4d).
    Intervention: Biological: Pandemic Influenza Vaccine
  • Placebo Comparator: Experimental: Group 4
    There will be 12 subjects in Group 4 that will receive a placebo consisting of buffer administered via intranasal spray on day 0 and day 28 (+/- 4d).
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48
December 2011
September 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy males and females in good general health, 19-49 years of age
  • Subjects must provide written consent
  • Willing to participate through study completion
  • Willing to undergo nasal washes and swabs and provide urine and blood samples per protocol for safety and immunogenicity analysis
  • Female of child-bearing age must have a negative urine pregnancy test and be stable on a reliable means of contraception.
  • Meet screening criteria for hematology, chemistry and urinalysis

Exclusion Criteria:

  • Pregnant (or possibly pregnant) and lactating women
  • Any flu/cold symptoms and/or fever greater than 101 degrees in 3 days prior to study enrollment
  • Any intranasal steroid medication administered in the 10 days prior to study enrollment
  • History of chronic rhinitis or presence of pre-existing nasal septal defects, nasal polyps or other gross abnormalities
  • Any previous nasal cautery or significant surgery for nasal septal defects
  • Any regular past or current use of intranasal illicit drugs or history of intravenous illicit drug use
  • Asthma that is greater than mild in severity
  • Diagnosed active Hepatitis B or C
  • HIV positive at screening
  • Known or suspected malignancy, leukemia, or lymphoma
  • Immunosuppressed, altered or compromised immune status as a consequence of disease or treatment with systemic corticosteroids
  • Receipt of an influenza vaccine within the past 6 months
  • Receipt of any vaccine in the past 30 days
  • Receipt of any investigational drug in the past 30 days
  • Known Diabetes mellitus
  • History of anaphylaxis or angioedema
  • Hypertension that is not well controlled
  • Any medical, psychiatric, or social condition, or occupational or other responsibility that, in the judgment of the investigator would serve to interfere or serve as a contraindication to, protocol adherence, assessment of safety or reactogenicity, or a participants's ability to give informed consent
Both
19 Years to 49 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00755703
H-0701-2, #1-UCI-AI-06205-01
Yes
Vaxin Inc.
Vaxin Inc.
Not Provided
Principal Investigator: Scott D. Parker, M.D. Alabama Vaccine Research Clinic, University of Alabama at Birmingham
Vaxin Inc.
September 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP